A1M Pharma has successfully conducted preclinical toxicology/safety studies within preeclampsia
A1M Pharma has successfully and according to plan conducted the first part of the company's toxicology/safety studies with the pharmaceutical compound in the company's candidate drug ROSGard™. In the studies, a maximum tolerated dose (MTD) has been established in two different animal models. These results will be used to establish the dosage levels to be used in the GLP-compliant toxicology studies.On the way towards clinical studies within treatment of preeclampsia, A1M Pharma is conducting several preclinical toxicology/safety studies. The first part, which aims to establish the maximum